Articles related to HEART FAILURE (HF)

The FDA approved Furoscix ReadyFlow, a subcutaneous furosemide autoinjector for edema associated with heart failure or chronic kidney disease. Clinical data demonstrated pharmacokinetic exposure and diuretic effects comparable to intravenous furosemide.

The ACC updated its expert consensus pathway for HFpEF, emphasizing diagnostic scoring, comorbidity assessment, and newer cardiometabolic therapies. The pathway reflects emerging evidence while remaining aligned with existing heart failure guidelines.

A Medicare cohort study found a median delay of 494 days between incident heart failure diagnosis and ATTR-CM diagnosis, with female sex, aortic stenosis, COPD, coronary artery disease, diabetes, and hypertension associated with longer diagnostic delays.

The Heart Failure Society of America released a scientific statement establishing diagnostic criteria and a treatment framework for heart failure with mildly reduced ejection fraction, a phenotypically heterogeneous group historically underrepresented in dedicated interventional trials.

A single-institution case series of 13 biopsy-proven hydroxychloroquine cardiomyopathy patients documented variable outcomes after drug cessation, ranging from full functional recovery to progression requiring advanced heart failure therapies.

A year‑in‑review article highlights major cardiovascular themes from 2025, including evolving approaches to hypertension, myocardial infarction management, and atrial fibrillation care.